The Prescription Drug Monitoring Program (PDMP) aims to improve the District’s ability to identify and reduce diversion of prescription drugs in an efficient and cost effective manner that will not impede the appropriate medical utilization of controlled substances; and to enhance patient care by providing prescription monitoring information that will assure legitimate use of controlled substances in health care, including palliative care, research and other medical and pharmacological uses.

PDMP Database Access

DC PDMP Presentation:
Click here to watch a presentation about the DC PDMP   

For dispensers: As of June 7, 2019, gabapentin is a covered substance for the DC PDMP. Dispensers are required to report dispensations of gabapentin to the DC PDMP.

NEW! All licensed prescribers and dispensers must register for the DC Prescription Drug Monitoring Program by July 31, 2019. Read the notice to practitioners or FAQs about mandatory registration for full details.

New! DC PDMP User Survey: This survey will be used to gauge initial PDMP use by registered users after  the mandatory registration. The information will be used to make improvements based off user feedback. Please take a few minutes complete the DC PDMP User Survey https://www.surveymonkey.com/r/DCPDMPSURVEY. 

Gateway Integration - grant funding is available for integration of PDMP data into electronic health records (EHRs), health information exchanges (HIEs), and pharmacy management systems. 

• Prescription Drug Monitoring Program Law
• Prescription Drug Monitoring Program Final Rulemaking
• Notices
• Frequently Asked Questions
• Frequently Asked Questions for Mandatory Registration
• Guides
• Forms
• PDMP Advisory Committee
  
  The District of Columbia Prescription Drug Monitoring Program
  Advisory Committee will hold a public meeting on:
  Tuesday, April 21, 2020 from 10:00 am until 12:00 pm
  At 899 North Capitol Street, NE, 2nd Floor, Room 216
  Washington, DC 20002
   

All questions and press inquiries regarding the Prescription Drug Monitoring Program must be submitted in writing. Interested parties may send inquiries by email to [email protected] or by regular mail to:

Prescription Drug Monitoring Program 
Health Regulation and Licensing Administration
899 N. Capitol Street, NE
2nd Floor
Washington, DC 20002